Johnson & Johnson (JNJ) closed the latest trading day at $166.09, indicating a +1.44% change from the previous session's end. This move outpaced the S&P 500's daily loss of 0.47%. Elsewhere, the Dow ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

We recently published a list of S&P 500 Dividend Aristocrats List: Sorted By Hedge Fund Sentiment. In this article, we are ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

Johnson & Johnson’s stock rose 1.1% on Thursday, reaching $159.56. Trading volume dropped significantly, with 1.7 million ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

The final trades of the day with the Fast Money traders.

Sanctuary Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.4% during the fourth quarter, ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...

Kenvue (NYSE: KVUE) stock is down since completing its spin-off from Johnson & Johnson (NYSE: JNJ) in August 2023. Kenvue is ...